| Careful selection of reference genes is required for reliable performance of RT-qPCR in human normal and cancer cell lines F Jacob, R Guertler, S Naim, S Nixdorf, A Fedier, NF Hacker, ... PloS one 8 (3), e59180, 2013 | 256 | 2013 |
| Emerging roles for phospholipase A2 enzymes in cancer KF Scott, M Sajinovic, J Hein, S Nixdorf, P Galettis, W Liauw, P de Souza, ... Biochimie 92 (6), 601-610, 2010 | 186 | 2010 |
| Specific glycosylation of membrane proteins in epithelial ovarian cancer cell lines: glycan structures reflect gene expression and DNA methylation status M Anugraham, F Jacob, S Nixdorf, AV Everest-Dass, ... Molecular & Cellular Proteomics 13 (9), 2213-2232, 2014 | 152 | 2014 |
| The Wnt gatekeeper SFRP4 modulates EMT, cell migration and downstream Wnt signalling in serous ovarian cancer cells CE Ford, E Jary, SSQ Ma, S Nixdorf, VA Heinzelmann-Schwarz, RL Ward PloS one 8 (1), e54362, 2013 | 110 | 2013 |
| Differential expression analysis of MIM (MTSS1) splice variants and a functional role of MIM in prostate cancer cell biology RD Loberg, CK Neeley, LL Adam-Day, Y Fridman, LN St John, S Nixdorf, ... International journal of oncology 26 (6), 1699-1705, 2005 | 86 | 2005 |
| Expression and regulation of MIM (Missing In Metastasis), a novel putative metastasis suppressor gene, and MIM-B, in bladder cancer cell lines S Nixdorf, MO Grimm, R Loberg, A Marreiros, PJ Russell, KJ Pienta, ... Cancer letters 215 (2), 209-220, 2004 | 84 | 2004 |
| The non-canonical Wnt ligand, Wnt5a, is upregulated and associated with epithelial to mesenchymal transition in epithelial ovarian cancer CE Ford, G Punnia-Moorthy, CE Henry, E Llamosas, S Nixdorf, J Olivier, ... Gynecologic oncology 134 (2), 338-345, 2014 | 73 | 2014 |
| Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients F Jacob, K Ukegjini, S Nixdorf, CE Ford, J Olivier, R Caduff, JP Scurry, ... PloS one 7 (2), e31885, 2012 | 73 | 2012 |
| A clinicopathological review of 33 patients with vulvar melanoma identifies c-KIT as a prognostic marker VA Heinzelmann-Schwarz, S Nixdorf, M Valadan, M Diczbalis, J Olivier, ... International journal of molecular medicine 33 (4), 784-794, 2014 | 61 | 2014 |
| Reliable in vitro studies require appropriate ovarian cancer cell lines F Jacob, S Nixdorf, NF Hacker, VA Heinzelmann-Schwarz Journal of ovarian research 7, 1-10, 2014 | 60 | 2014 |
| Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells F Jacob, MP Hitchins, A Fedier, K Brennan, S Nixdorf, NF Hacker, R Ward, ... BMC molecular biology 15, 1-13, 2014 | 48 | 2014 |
| Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma TR Jue, K Nozue, AJ Lester, S Joshi, LBW Schroder, SP Whittaker, ... Journal of translational medicine 15, 1-8, 2017 | 45 | 2017 |
| Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma M Anugraham, F Jacob, AV Everest‐Dass, A Schoetzau, S Nixdorf, ... Molecular oncology 11 (11), 1595-1615, 2017 | 26 | 2017 |
| Alterations in the mitochondrial responses to PENAO as a mechanism of resistance in ovarian cancer cells S Decollogne, S Joshi, SA Chung, PP Luk, RX Yeo, S Nixdorf, A Fedier, ... Gynecologic oncology 138 (2), 363-371, 2015 | 23 | 2015 |
| Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response? A Lester, R Rapkins, S Nixdorf, M Khasraw, K McDonald Clinical and Translational Oncology 19, 273-278, 2017 | 17 | 2017 |
| The role of TP53 gain-of-function mutation in multifocal glioblastoma LR Olafson, M Gunawardena, S Nixdorf, KL McDonald, RW Rapkins Journal of Neuro-oncology 147, 37-47, 2020 | 14 | 2020 |
| Elevated levels of prostate‐specific antigen (PSA) in prostate cancer cells expressing mutant p53 is associated with tumor metastasis S Downing, C Bumak, S Nixdorf, K Ow, P Russell, P Jackson Molecular Carcinogenesis: Published in cooperation with the University of …, 2003 | 14 | 2003 |
| Advances in lipid-based nanocarriers for breast cancer metastasis treatment I Joun, S Nixdorf, W Deng Frontiers in Medical Technology 4, 893056, 2022 | 3 | 2022 |
| Whole genome and biomarker analysis of patients with recurrent glioblastoma on bevacizumab: a subset analysis of the CABARET trial LR Olafson, AH Siddell, KM Field, M Byrnes, RW Rapkins, B Ng, S Nixdorf, ... Journal of Clinical Neuroscience 70, 157-163, 2019 | 3 | 2019 |
| P-1 Antigen is Present on the Serous Ovarian Cancer Cell Line, IGROV1, Correlating with A4GALT Overexpression and Altered Cell Behaviour F Jacob, BWC Tse, R Guertler, S Nixdorf, NV Bovin, NF Hacker, ... Glycobiology 21 (11), 1519-1520, 2011 | 3 | 2011 |
